NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CRVS Stock Alerts $1.90 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.90▼$2.0050-Day Range$1.88▼$2.4152-Week Range$0.61▼$4.19Volume163,443 shsAverage Volume201,079 shsMarket Capitalization$93.18 millionP/E RatioN/ADividend YieldN/APrice Target$6.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Corvus Pharmaceuticals alerts: Email Address Corvus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside248.7% Upside$6.63 Price TargetShort InterestBearish3.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.56) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.86 out of 5 starsMedical Sector689th out of 946 stocksPharmaceutical Preparations Industry319th out of 434 stocks 3.3 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.63, Corvus Pharmaceuticals has a forecasted upside of 248.7% from its current price of $1.90.Amount of Analyst CoverageCorvus Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.44% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVS. Previous Next 2.6 News and Social Media Coverage News SentimentCorvus Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Corvus Pharmaceuticals this week, compared to 1 article on an average week.Search Interest26 people have searched for CRVS on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.79% of the stock of Corvus Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.56) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Read More CRVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRVS Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comCRVS Apr 2024 4.000 putMarch 13, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024March 19, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 10, 2024 | americanbankingnews.comFinancial Review: Anebulo Pharmaceuticals (NASDAQ:ANEB) vs. Corvus Pharmaceuticals (NASDAQ:CRVS)March 9, 2024 | finance.yahoo.comWe Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth CarefullyFebruary 17, 2024 | finance.yahoo.comCRVS Mar 2024 3.000 putFebruary 12, 2024 | msn.comCorvus Edges up on Disclosing DataFebruary 12, 2024 | finance.yahoo.comCorvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock UpMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 8, 2024 | marketwatch.comCorvus Pharmaceuticals Shares Rise on Orphan Drug DesignationFebruary 8, 2024 | msn.comCorvus lymphoma drug gets FDA orphan drug statusFebruary 8, 2024 | finance.yahoo.comCorvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaFebruary 6, 2024 | finance.yahoo.comCorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerJanuary 23, 2024 | finance.yahoo.comCorvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellJanuary 5, 2024 | finance.yahoo.comIndividual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last weekDecember 13, 2023 | markets.businessinsider.comMaintaining Hold Rating on Corvus Pharmaceuticals Amid Steady but Unspectacular Clinical ProgressDecember 7, 2023 | msn.comAre Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?November 21, 2023 | finance.yahoo.comIs Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?November 9, 2023 | morningstar.comCorvus Pharmaceuticals Inc CRVSNovember 8, 2023 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | finance.yahoo.comQ3 2023 Corvus Pharmaceuticals Inc Earnings CallNovember 7, 2023 | finance.yahoo.comCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comCorvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & ExpositionNovember 1, 2023 | finance.yahoo.comCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune DiseasesOctober 31, 2023 | finance.yahoo.comCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023October 1, 2023 | finance.yahoo.comHere's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn SituationSeptember 12, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)See More Headlines Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2021Today3/19/2024Next Earnings (Estimated)3/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$6.63 High Stock Price Target$12.00 Low Stock Price Target$3.50 Potential Upside/Downside+248.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.76% Return on Assets-51.08% Debt Debt-to-Equity RatioN/A Current Ratio4.53 Quick Ratio4.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book1.57Miscellaneous Outstanding Shares49,040,000Free Float33,690,000Market Cap$93.18 million OptionableOptionable Beta1.04 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Richard A. Miller M.D. (Age 73)Co-Founder, President, CEO & Chairman of the Board Comp: $306kDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Director Comp: $47kMr. Leiv Lea (Age 70)Chief Financial Officer Comp: $388.73kDr. William Benton Jones Ph.D. (Age 58)Senior Vice President of Pharmaceutical Development Comp: $346.42kDr. James T. Rosenbaum M.D.Senior Vice President of ResearchMr. Jeffrey S. ArcaraChief Business OfficerMore ExecutivesKey CompetitorsAnnovis BioNYSE:ANVSBarinthus BiotherapeuticsNASDAQ:BRNSCervoMedNASDAQ:CRVOCarisma TherapeuticsNASDAQ:CARMVaxxinityNASDAQ:VAXXView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 19,100 shares on 2/15/2024Ownership: 0.000%Simplex Trading LLCBought 6,200 shares on 2/2/2024Ownership: 0.000%Towerview LLCBought 94,395 shares on 2/1/2024Ownership: 0.891%Linda GraisBought 10,000 shares on 5/15/2023Total: $24,500.00 ($2.45/share)View All Insider TransactionsView All Institutional Transactions CRVS Stock Analysis - Frequently Asked Questions Should I buy or sell Corvus Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRVS shares. View CRVS analyst ratings or view top-rated stocks. What is Corvus Pharmaceuticals' stock price target for 2024? 3 Wall Street research analysts have issued 12-month price targets for Corvus Pharmaceuticals' shares. Their CRVS share price targets range from $3.50 to $12.00. On average, they predict the company's stock price to reach $6.63 in the next year. This suggests a possible upside of 248.7% from the stock's current price. View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts. How have CRVS shares performed in 2024? Corvus Pharmaceuticals' stock was trading at $1.76 at the start of the year. Since then, CRVS shares have increased by 8.0% and is now trading at $1.90. View the best growth stocks for 2024 here. When is Corvus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our CRVS earnings forecast. How can I listen to Corvus Pharmaceuticals' earnings call? Corvus Pharmaceuticals will be holding an earnings conference call on Tuesday, March 19th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) announced its earnings results on Sunday, October, 31st. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.24). What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO? 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO). When did Corvus Pharmaceuticals IPO? (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Towerview LLC (0.89%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRVS) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.